shared knowledge shared progress
Lhasa Limited releases new data to it's Nitrites in Excipients project usersLhasa Limited is pleased to release new data to it's Nitrites in Excipients project users.
04 June 2021
25 May 2021
26 April 2021
20 tips for nitrosamine impurity assessmentMany readers will be aware of the risk posed by nitrosamine impurities, as an ongoing pharmaceutical industry hot topic. In July 2021 ANVISA published their guidance for assessment and control of potentially carcinogenic nitrosamines in active pharmaceutical ingredients and drug products. To discuss this topic, we invited knowledgeable speakers from ANVISA, Industry - GSK and Libbs Farmacêutica - and Lhasa to give their perspectives on this topic. This article details the top 20 take away points from the workshop for quick and easy consumption - enjoy!
05 August 2021
08 April 2021
25 January 2021
Lhasa Limited releases Nexus 2.4 with enhanced ICH M7 expert review supportTo enhance expert review assessment support, Nexus 2.4 includes a new flag to alert the reviewer when a compound is in the ICH M7 “cohort of concern”.
22 July 2021
How to make mutagenicity assessment a simpler taskA key requirement of ICH M7 is to use two complementary (Q)SAR methodologies, one expert rule-based and the second statistical-based. This blog article recognises the benefits provided when in silico systems are integrated to provide a full ICH M7 assessment in one environment.
Discover how Lhasa Limited can help make mutagenicity assessment a simpler task, in this article!
15 September 2021
September 2021Sarah Nexus
August 2021Zeneth
August 2021MirabilisViticKaptis
Lhasa Limited releases Nexus 2.4 with enhanced ICH M7 expert review supportTo enhance expert review assessment support, Nexus 2.4 includes a new flag to alert the reviewer when a compound is in the ICH M7 “cohort of concern”.
22 July 2021
04 June 2021
25 May 2021
How to make mutagenicity assessment a simpler taskA key requirement of ICH M7 is to use two complementary (Q)SAR methodologies, one expert rule-based and the second statistical-based. This blog article recognises the benefits provided when in silico systems are integrated to provide a full ICH M7 assessment in one environment.
Discover how Lhasa Limited can help make mutagenicity assessment a simpler task, in this article!
15 September 2021
09 September 2021
23 August 2021
Lepley L;This graphic provides an overview of the key differences between Derek Nexus and Sarah Nexus. Core areas considered are the data on which the predictions are based, the methodology applied, scope of the alert and interpretability.
© 2021 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).
Apart from the free survey software, we also have access to QuestionPro's free survey templates . We've found many of them useful and powerful to collect insights from various stakeholders of our organization.
